Saul Fink - Q32 Bio Chief Officer
| QTTB Stock | 27.04 0.24 0.88% |
Executive
Saul Fink is Chief Officer of Q32 Bio
| Address | 830 Winter Street, Waltham, MA, United States, 02451 |
| Phone | 781 999 0232 |
| Web | https://www.q32bio.com |
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| David Beker | Air Lease | N/A | |
| Courtney McKeown | Air Lease | N/A | |
| Wanjiku JD | 53 | ||
| Malik Ducard | 51 | ||
| Matt Madrigal | N/A | ||
| Julia Donnelly | 41 | ||
| Joseph Donegan | Willscot Mobile Mini | 73 | |
| Jason Berg | U Haul Holding | 51 | |
| Jason Arnold | Air Lease | N/A | |
| Laurence Respino | U Haul Holding | 63 | |
| Graeme Parkes | Willscot Mobile Mini | 51 | |
| Daniel Verwholt | Air Lease | N/A | |
| Jeremy King | 55 | ||
| Doniel Sutton | 50 | ||
| Wanjiku Walcott | 53 | ||
| Eric Hoogenkamp | Air Lease | N/A | |
| Christine Flores | 45 | ||
| Bill Watkins | N/A | ||
| Sally Shanks | Willscot Mobile Mini | 47 | |
| Tse Yang | 47 | ||
| Felicia Gorcyca | Willscot Mobile Mini | 45 | |
Q32 Bio Leadership Team
Elected by the shareholders, the Q32 Bio's board of directors comprises two types of representatives: Q32 Bio inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Q32. The board's role is to monitor Q32 Bio's management team and ensure that shareholders' interests are well served. Q32 Bio's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Q32 Bio's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Saul Fink, Chief Officer | ||
| Shelia Violette, Chief Cofounder | ||
| Jodie Morrison, Secretary CEO | ||
| Kathryn MBA, Manufacturing Chemistry | ||
| Lee MBA, Chief Officer | ||
| Maria MPH, Executive Operations | ||
| David JD, Senior People | ||
| David MD, President Director |
Q32 Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Q32 Bio a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Operating Margin | 5.18 % | ||||
| Current Valuation | 468.77 M | ||||
| Shares Outstanding | 12.06 M | ||||
| Shares Owned By Insiders | 9.14 % | ||||
| Shares Owned By Institutions | 73.77 % | ||||
| Number Of Shares Shorted | 686.07 K | ||||
| Price To Book | 16.61 X | ||||
| Revenue | 1.16 M | ||||
| EBITDA | (86.5 M) | ||||
| Net Income | (112.96 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Q32 Bio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Q32 Bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Q32 Bio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Q32 Bio Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Q32 Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For information on how to trade Q32 Stock refer to our How to Trade Q32 Stock guide.You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Q32 Bio. If investors know Q32 will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Q32 Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.50) | Revenue Per Share (1.24) |
The market value of Q32 Bio is measured differently than its book value, which is the value of Q32 that is recorded on the company's balance sheet. Investors also form their own opinion of Q32 Bio's value that differs from its market value or its book value, called intrinsic value, which is Q32 Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Q32 Bio's market value can be influenced by many factors that don't directly affect Q32 Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Q32 Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Q32 Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Q32 Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.